CAJ | 학술논문

目的：观察重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及对胸水血管内皮生长因子（ VEGF）、低氧诱导因子1α（ HIF-1α）水平和血清肿瘤标志物的影响。方法以非小细胞肺癌并发恶性胸腔积液的患者60例为观察对象，随机分为常规治疗组和干预治疗组，每组30例。常规治疗组给予顺铂胸腔灌注治疗，干预治疗组在此基础上加用重组人血管内皮抑制素胸腔灌注。观察两组患者胸腔积液的缓解率和不良反应发生率；检测患者胸水VEGF、HIF-1α水平及血清肿瘤标志物的变化。结果两组患者间不良反应发生率无显著差异。与常规治疗组相比较，干预治疗组患者的胸腔积液总缓解率高，胸水VEGF、HIF-1α水平及血清肿瘤标志物的水平下降更明显，差异具有统计学意义。结论重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的不良反应与单用顺铂大致相似，且具有更好的疗效。
목적：관찰중조인혈관내피억제소연합순박치료비소세포폐암악성흉강적액적료효급대흉수혈관내피생장인자（ VEGF）、저양유도인자1α（ HIF-1α）수평화혈청종류표지물적영향。방법이비소세포폐암병발악성흉강적액적환자60례위관찰대상，수궤분위상규치료조화간예치료조，매조30례。상규치료조급여순박흉강관주치료，간예치료조재차기출상가용중조인혈관내피억제소흉강관주。관찰량조환자흉강적액적완해솔화불량반응발생솔；검측환자흉수VEGF、HIF-1α수평급혈청종류표지물적변화。결과량조환자간불량반응발생솔무현저차이。여상규치료조상비교，간예치료조환자적흉강적액총완해솔고，흉수VEGF、HIF-1α수평급혈청종류표지물적수평하강경명현，차이구유통계학의의。결론중조인혈관내피억제소연합순박치료비소세포폐암악성흉강적액적불량반응여단용순박대치상사，차구유경호적료효。
Objective To observe the efficacy of Endostar combined with cisplatin in treatment of malignant pleural effusion in patients with non-small cell lung cancer and influence on level of VEGF and HIF-1αin pleural effusion and serum tumor markers. Methods Sixty pa-tients with non-small cell lung cancer associated with pleural effusion were randomly divided into routine treatment group and Endostar treatment group,each group with 30 cases. Patients in routine treatment group were given with cisplatin intrapleural infusion therapy,and patients in En-dostar treatment group were administrated with thoracic perfusion of Endostar on the basis of cisplatin treatment. The remission rate of pleural effu-sion,the incidence of adverse reactions,and changes of VEGF and HIF-1αin pleural effusion and serum level of tumor markers in patients of these 2 groups were observed. Results There was no significant difference in incidence of adverse reactions,and the total remission rate of pleural effusion in patients of Endostar treatment group was higher than that of patients in routine treatment group,levels of VEGF and HIF-1αin pleural effusion,and levels of serum tumor markers were more significantly decreased. Conclusion The efficacy of Endostar combined with cisplatin in treatment of patients with non small cell lung cancer associated with malignant pleural effusion was more significant than that of patients treated with cisplatin alone,and the incidence rates of adverse reactions are similar in these 2 groups.